Abstract
The alkaloid nicotine, a major addictive component of tobacco, exerts anti-inflammatory and immunemodulating activities on multiple cell types, such as T cells, B cells, dendritic cells, mononuclear phagocytes and polymorphonuclear leukocytes, in lung, spleen, liver, kidney and gastrointestinal tract. In addition, nicotine may blunt pro-inflammatory cytokine release, with prominent effects on T helper type 1 (Th1) and Th17 cytokines. The nonneuronal α7-nicotinic cholinergic receptors are a primary target for nicotine through the JAK2 and STAT3/NF-κB pathways, ultimately mediating the inhibition of pro-inflammatory gene transcription. The present paper reviews the growing evidence in favor of detrimental as well as beneficial effects of nicotine and other α7-nicotininc receptor agonists in pre-clinical models of organ-specific and systemic inflammatory and autoimmune diseases. These data may portend favorable implications for the targeted treatment of chronic and debilitating human disorders, such as diabetes, arthritis, asthma and inflammatory bowel disease, with α7-selective ligands.
Keywords: Nicotinic Receptors, immunity, inflammation, cytokines, cholinergic, anti-inflammatory, autoimmune encephalomyelitis, allergic asthma, arthritis, diabetes
Current Drug Targets
Title:The Yin and Yang of Non-Neuronal α7-Nicotinic Receptors in Inflammation and Autoimmunity
Volume: 13 Issue: 5
Author(s): Perla Filippini, Alfredo Cesario, Massimo Fini, Franco Locatelli, Sergio Rutella
Affiliation:
Keywords: Nicotinic Receptors, immunity, inflammation, cytokines, cholinergic, anti-inflammatory, autoimmune encephalomyelitis, allergic asthma, arthritis, diabetes
Abstract: The alkaloid nicotine, a major addictive component of tobacco, exerts anti-inflammatory and immunemodulating activities on multiple cell types, such as T cells, B cells, dendritic cells, mononuclear phagocytes and polymorphonuclear leukocytes, in lung, spleen, liver, kidney and gastrointestinal tract. In addition, nicotine may blunt pro-inflammatory cytokine release, with prominent effects on T helper type 1 (Th1) and Th17 cytokines. The nonneuronal α7-nicotinic cholinergic receptors are a primary target for nicotine through the JAK2 and STAT3/NF-κB pathways, ultimately mediating the inhibition of pro-inflammatory gene transcription. The present paper reviews the growing evidence in favor of detrimental as well as beneficial effects of nicotine and other α7-nicotininc receptor agonists in pre-clinical models of organ-specific and systemic inflammatory and autoimmune diseases. These data may portend favorable implications for the targeted treatment of chronic and debilitating human disorders, such as diabetes, arthritis, asthma and inflammatory bowel disease, with α7-selective ligands.
Export Options
About this article
Cite this article as:
Perla Filippini, Alfredo Cesario, Massimo Fini, Franco Locatelli, Sergio Rutella , The Yin and Yang of Non-Neuronal α7-Nicotinic Receptors in Inflammation and Autoimmunity , Current Drug Targets 2012; 13 (5) . https://dx.doi.org/10.2174/138945012800399008
DOI https://dx.doi.org/10.2174/138945012800399008 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chronopharmaceutics Based Modern Colon Specific Drug Delivery Systems
Current Drug Discovery Technologies Common Issues Among Asthma, Epilepsy, and Schizophrenia: From Inflammation to Ca<sup>2+</sup>/cAMP Signalling
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Role of TRP Channels in Allergic Inflammation and its Clinical Relevance
Current Medicinal Chemistry The Anti-Inflammatory Role of Annexin-1 in Arthritis
Current Rheumatology Reviews Mycoplasma pneumoniae: Does it have a Role in Asthma Pathogenesis?
Current Pediatric Reviews Experimental Drugs for Neuropathic Pain
Current Neuropharmacology Structural Organization of the Regulatory Domain of Human 5- Lipoxygenase
Current Protein & Peptide Science Regulation of Innate Immunity Signaling and its Connection with Human Diseases
Current Drug Targets - Inflammation & Allergy Therapeutic Use of Heat Shock Protein 70
Recent Patents on DNA & Gene Sequences Measuring Control: How can Response to Asthma Treatment be Measured?
Current Pediatric Reviews Antivirals Used for Influenza Chemoprophylaxis
Current Medicinal Chemistry Drug Disposition in Pathophysiological Conditions
Current Drug Metabolism Targeting Fibrosis in Systemic Sclerosis
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel Metal Nanoparticles Stabilized with (2R,4R)-2,4-bis(diphenylphosphino) Pentane on SiO2. Their Use as Catalysts in Enantioselective Hydrogenation Reactions
Current Organic Chemistry Cyclophilins in Atherosclerosis: A New Therapeutic Target?
Current Pharmaceutical Design Radiological Presentation of H1N1 Influenza in the 2017 Outbreak in India and Correlation with Patient Outcome
Current Respiratory Medicine Reviews Nasal Polyposis: From Pathogenesis to Treatment, An Update
Inflammation & Allergy - Drug Targets (Discontinued) siRNA Therapy, Challenges and Underlying Perspectives of Dendrimer as Delivery Vector
Current Pharmaceutical Design The Physiology of Nitric Oxide: Control and Consequences
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Extending the Clinical Horizons of Mucosal Bacterial Vaccines: Current Evidence and Future Prospects
Current Drug Targets